**Name of Journal: *World Journal of Cardiology***

**ESPS Manuscript NO: 19014**

**Manuscript Type: TOPIC HIGHLIGHT**

**2015 Advances in Nonalcoholic Fatty Liver Disease**

**Psoriasis, non-alcoholic fatty liver disease, and cardiovascular disease: Three different diseases for a unique background**

Ganzetti G *et al*. Psoriasis, NAFLD, and cardiovascular disease

**Giulia Ganzetti, Anna Campanati, Elisa Molinelli, Annamaria Offidani**

**Giulia Ganzetti, Anna Campanati, Elisa Molinelli, Annamaria Offidani,** Dermatological Unit, Department of Clinical and Molecular Sciences, Polytehnic Marche University, 60126 Ancona, Italy

**Author contributions:** Ganzetti G, Campanati A and Molinelli E wrote the paper; Offidani A supervised the work.

**Conflict-of-interest statement:** All authors declare no conflict of interest.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Correspondence to: Dr. Giulia Ganzetti, MD, PhD,** Dermatological Unit, Department of Clinical and Molecular Sciences, Polytehnic Marche University,Via Conca, 71, 60126 Ancona, Italy. giulia.ganzetti@alice.it

**Telephone:** +39-71-5965686

**Fax:** +39-71-5963446

**Received:** April 28, 2015

**Peer-review started:** May 6, 2015

**First decision:** July 22, 2015

**Revised:** October 8, 2015

**Accepted:** December 17, 2015

**Article in press:**

**Published online:**

**Abstract**

Psoriasis is a chronic inflammatory immune-mediated skin diseases, frequently associated to systemic comorbidities. According to recent data, patients with psoriasis show a greater prevalence of metabolic syndrome, which confers a higher cardiovascular risk factors. The link between these pathological conditions appears to be a chronic low-grade inflammatory status. The aim of this review is to focus on the multiple epidemiological and physio-pathogenetic aspects linking non-alcoholic fatty liver disease psoriasis, and cardiovascular disease.

**Key words:** Psoriasis; Non-alcoholic fatty liver disease; Cardiovascular risk

**© The Author(s) 2015.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** The review focuses on the multiple physio-pathogenetic aspects of the possible link between psoriasis, non-alcoholic fatty liver disease, and cardiovascular disease emphasizing the recent scientific data. The multidisciplinary approach to psoriatic patients appears mandatory to treat concomitant psoriasis-related comorbidity evaluating the risk/benefit of both biologic and non-biologic therapies.

Ganzetti G, Campanati A, Molinelli E, Offidani A. Psoriasis, non-alcoholic fatty liver disease, and cardiovascular disease: Three different diseases for a unique background. *World J Cardiol* 2015; In press

**INTRODUCTION**

Psoriasis is a chronic inflammatory relapsing disease affecting 1%-4% of the general population[1].

Despite psoriasis is a skin disorder clinically characterized by red scaly plaques, it is no more limited to the skin surface but it has been identified as a complex clinical entity with a systemic involvement. Many comorbidities have been associated to psoriatic disease, as psoriatic arthritis (PsA), metabolic syndrome (MetS), cardiovascular disease (CVD), non-alcoholic fatty liver disease (NAFLD), inflammatory bowel disease, uveitis, depression and malignancy[2-5].

An higher prevalence of cardiovascular risk factors, as dyslipidemia and obesity, have been reportedin psoriatic patients[4,6].

NAFLD is one of the most frequent cause of chronic liver disease with a prevalence of 10%-25% in general population[7].

NAFLD is now considered the hepatic manifestation of the MetS and a prospective cohort study have evidenced that MetS and its components may independently predict the risk of NAFLD[8,9].

NAFLD itself represents a further independent cardiovascular risk factor for atherosclerosis which is likely linked to arterial stiffness[10,11].

The aim of the present review is to focus on the association of psoriasis, NAFLD and CVD focusing on epidemiologic data and the underlying common pathogenic process.

**NAFLD AND PSORIASIS**

The prevalence of the MetS has been estimated about 15%-25% in general population, appearing significantly higher and approximately increasing of about 3-fold in psoriatic patients, as documented by many case-controls study[12-16].

The association between psoriasis and MetS is directly correlated to the severity of psoriasis resulting independent from the presence of obesity in psoriatics[17-19].

NAFLD is defined as a spectrum of hepatic pathologies ranging from fatty liver disease (steatosis) to steatohepatitis (NASH) with the risk of evolution in cirrhosis and hepatocellular carcinoma[20].

As MetS, NAFLD is more prevalent in psoriatic patients than in general population. Roberts *et al*[21] enrolled a cohort of 103 psoriatic patients emphasizing that NAFLD affected about 47% of patients and one of five of them showed NASH.

A large prospective population-based cohort study had been conducted by Van der Voort *et al*[22] in patients older than 55 years. Among 2292 participants, 5.1% of the population study was affected by psoriasis with a prevalence of NAFLD of about 46.2% in psoriatic patients *vs* 33.3% in subjects without psoriasis.

Furthermore, a recent meta-analysis have documented that patients with PsA and patients with moderate to severe psoriasis showed a significantly greater risk of NAFLD compared with those with mild psoriasis[23].

AST/ALT ratio is considered an independent predictive factor for liver fibrosis in patients with NAFLD: Significantly higher AST/ALT ratio and higher non-invasive fibrosis scores have been detected in patients with both psoriasis and NAFLD compared to controls with only NAFLD[24].

**CARDIOVASCULAR RISK FACTORS AND PSORIASIS**

MetS confers an increased risk of cardiovascular events and mortality due to CVDs[25,26]. Psoriatic patients show a higher prevalence of cardiovascular risk factors which are shared by NAFLD and CVD, thus representing the trade union between these pathologies. Obesity represents a great burden in global individual’s health significantly increasing morbidity and mortality[27].

Data from large cohort studies have shown that among 163517 enrolled individuals, 17% were obese (11465 men and 16612 women).Thus, obesity represents a great public health problem reaching worrying proportions both in pediatric and adult population[27].

As demonstrated by recent observational studies, psoriatic population may have a higher risk of over-weight and obesity with the consequent higher risk of MetS’ components[28].

Danielsen *et al*[29] have conducted a recent population-based study confirming an increased prevalence of Mets in patients affected by psoriasis compared to controls. Interestingly, a different trend was emphasized between genders: a 3.8-times higher odds of MetS were found in young women (30 years) with an odds ratio reduction with increasing age. Conversely, men showed a 1.35-times higher odds ratio of Mets, independently from age.

Moreover, a direct correlation between severity of psoriasis and obesity has been evidenced in a recent meta-analysis: A 1.46 odds ratio was found in mild psoriasis and a 2.23 odds ratio in severe psoriasis[22,30].

Dyslipidemia is a further risk factor which is shared by NAFLD, psoriasis and CVD. Observational studies have detected a lipid metabolism alteration in psoriatic patients contributing to a dyslipidemic profile and conferring a significant cardiovascular risk[31].

Psoriatic children present high total cholesterol plasma levels and high percentage content of total cholesterol and of the cholesterol/protein ratio in LDL and in HDL[32].

Moreover, an increased odds of hypertriglyceridemia, significantly reduced levels of HDL cholesterol (< 40 mg/dL), hyperlipoproteinemia and hypercholesterolemia have been identified in psoriatic populations[31,33,34].

As for obesity, a positive correlation was found between dyslipidemia and severity of psoriasis with an increased odds of 1.10-3.38 in mild psoriasis and 1.36-5.55 in severe psoriasis[35,36].

The dyslipidemic profile appears extremely relevant: in fact, it is known that hypercholesterolemia can lead to atherosclerosis and coronary heart disease. In animal models, adipocytes’ differentiation and maturation can be altered by cholesterol accumulation in pre-adypocites leading to adipocyte hypertrophy and adipose tissue inflammation. In humans, it has been demonstrated that hypercholesterolemia leads to an unbalance in the pro- and anti-inflammatory adipocytokines’ production by adipose tissue[37].

CVD**S AND PSORIASIS**

CVDs include atherosclerosis, hypertension, ischemic heart disease, myocardial infarction, stroke and arrhythmias[4].

An increased incidence of cardiovascular risk factors and major cardiovascular events has been found in psoriasis[4,5,15].

Mehta *et al*[38] performed a cohort study on patients affected by severe psoriasis evidencing a further 6.2% absolute risk of a 10-year rate major cardiovascular events and suggesting the possible role of severity of the disease in the pathogenesis of CVD.

In particular, a 6-year reduction in life expectancy has been evidenced in patients with severe psoriasis[39].

Although the role of the extension on psoriasis-involved body sites has not been completely elucidated, study populations showed that a wide skin involvement and the presence of inter-gluteal lesions may represent independent predictor factors of CVD in psoriatics[40].

A prospective, population-based cohort study had been conducted by Gelfand *et al*[41] in 2006 evaluating the risk of myocardial infarction (MI) in psoriatic patients. The authors found that psoriatics had a higher incidence of MI which resulted positively correlated with disease severity, resulting 4.04 per 1000 person-years (95%CI: 3.88-4.21) in mild psoriasis and 5.13 per 1000 person-years (95%CI: 4.22-6.17) in severe psoriasis. Moreover, the risk of MI was higher in young 30-year-old psoriatic patients persisting higher after adjustment for major risk factors for MI and suggesting that psoriasis itself confers an independent risk of MI.

This aspect was also confirmed by Brauchhli *et al*[42]*,* who found the highest incidence rate ratio of MI in psoriatic patients ranging 30-39 years with severe skin disease.

The concomitant presence of PsA seems to lead to an increased risk of non-fatal MI: A risk up to 10% of CVD disease within 10 years of PsA incidence has been identified in most of newly diagnosed PsA patients[43,44].

A retrospective study has shown that the concomitant presence of arterial hypertension (AH) and diabetes mellitus (DM) enhances the risk of CVD in PsA patients. The prevalence of AH and DM resulted significantly greater in PsA patients who have had CVD compared to those without CVD: The prevalence of AH was 95% *vs* 45% respectively and the prevalence of DM was 60% *vs* 19% respectively. These aspects have important repercussions on early recognition and targeted treatment of comorbidities in psoriatic patients in order to reduce morbidity and mortality[45].

An association between psoriasis and atherosclerotic disease has been recognized. A cross-sectional study conducted by Yiu *et al*[46] had evaluated the prevalence and the extent of coronary and carotid atherosclerosis in 70 psoriatic patients compared to age- and gender-matched healthy controls. Psoriatic patients showed a 10-fold increased risk of subclinical coronary atherosclerosis and a premature diffuse coronary and carotid atherosclerosis.

The subclinical vascular atherosclerosis in psoriasis has been also studied by Balci *et al*[47] on 43 psoriatic patients without cardiovascular risk factors and 43 healthy controls matched for sex and age. Significantly higher mean intima-media thickness values of the right, left and averaged common carotid arteries had been detected in psoriatics than in controls (0.607 ± 0.144 mm *vs* 0.532 ± 0.101 mm, 0.611 ± 0.157 mm *vs* 0.521 ± 0.117 mm, and 0.609 ± 0.146 mm *vs* 0.526 ± 0.104 mm, respectively). Conversely, the mean flow-mediated dilatation and nitroglycerin-induced dilatation values resulted significantly lower in patients with psoriasis than in controls (13.36 ± 6.39 mm *vs* 19.60 ± 11.23 mm and 21.08 ± 8.38 mm *vs* 26.85 ± 12.38 mm; *P* = 0.002 and *P* = 0.013, respectively).

It is well documented that calcium exerts an important role in atherosclerosis being an important index of subclinical atherosclerosis and greatly impacting on the atherosclerotic plaque burden[48].

A recent case-control study had been conducted on 40 patients with psoriasis and 42 controls matched for age, sex, and cardiovascular risk profile in order to examine the prevalence of coronary calcification. The same prevalence of calcified and non-calcified atherosclerotic coronary lesions had been evidenced in both groups[49]. Conversely, emerging data show that patients with psoriasis have higher coronary calcium score (CAC), which was directly correlated to psoriasis severity[50].

A cross-sectional study had been conducted on Mediterranean population aiming to determine the prevalence of ischemic CAD in patients with psoriasis establishing a significant independent association between psoriasis and CAD[51].

The coronary microvascular function has been evaluated in psoriatic patients by echocardiographic examination to emphasize the coronary flow reserve (CFR). A coronary impairment had been shown with a reduction in CFR and with a positive inverse correlation between CFR and PASI score, disease duration and C-reactive protein[52].

Interestingly, it has been recently documented that psoriasis and coronary artery disease share similarities in coronary function and myocardial deformation with a subclinical left ventricular deformation. This aspect may contribute to vascular dysfunction in psoriatic patients increasing the risk of coronary artery disease[53].

The early detection of specific inflammatory biomarkers implicated in CVDs and in subclinical atherosclerosis remains a fundamental item to promptly identify the cardiovascular risk in this population[54].

New data have emerged from literature study on this topic. In particular, N-terminal pro B-type natriuretic peptide (NT-proBNP) is a molecule secreted by the ventricular myocardium in response to increased ventricular stretch and it plays an important role as predictor of cardiovascular mortality, of negative outcome in stroke and of left ventricular systolic dysfunction[54].

Significantly higher serum levels of NT-proBNP resulted in 73 male psoriatic patients compared to controls with a direct correlation with disease duration[55].

These results appear relevant in the light of echocardiographic abnormalities found by Biyik *et al*[56], who showed left ventricle’s hypertrophy, diastolic dysfunction and wall motion alterations in patients affected by psoriasis. Moreover, a higher frequency of mitral and tricuspid valves’ prolapse had been diagnosed in psoriatics.

Another useful biomarker is homocysteine which is considered an independent risk factor for CVD by promoting oxidative stress, lipoperoxidation and endothelial cell dysfunction. Moreover, hyperomocysteinemia is considered an independent risk factor for CVD conferring an elevated risk of atherosclerosis, stroke and peripheral occlusive vascular diseases[57].

Homocysteine plasma levels has been evaluated in psoriasis showing significantly higher levels compared to healthy subjects, with a positive correlation with disease severity. No correlation had been found between homocysteine serum levels and disease duration or the presence of arthritis[57,58].

Furthermore, high homocysteine plasma levels and reduced folic acid plasma levels in psoriatic patients seem to be implicated in a pro-thrombotic state[59].

A new interesting biomarker of vascular damage had been recently studied in psoriatic patients, YKL-40. YKL-40 belongs to chitinase family and it has been detected in atherosclerotic plaque contributing to endothelial dysfunction (ED) and predicting early vascular damage in diseases with high cardiovascular risk. Increased levels of YKL-40 has been found in inflammatory conditions, as rheumatoid arthritis, osteoarthritis and systemic lupus erythematosus and Crohn’s disease[60,61].

As concern psoriasis, a case-control study on 48 psoriatic patients has emphasized a statistically significant elevation of YKL-40 levels. These data had been confirmed by Erfan *et al*[60], who had also performed ultrasonography in order to identify ED. Psoriatic patients with ED showed higher YKL-40 serum levels than healthy controls without ED; moreover, psoriatic patients with concomitant cardiovascular risk factors, as smoking, obesity and diabetes, showed higher YKL-40 levels that those without[62].

The higher cardiovascular risk in psoriasis appears also linked to the increased prevalence and incidence of hypertension. In fact, hypertension is a well-established risk factor for CVDs and cardiovascular mortality[63].

The association between psoriasis and hypertension has been evaluated in a recent meta-analysis conducted by Armstrong *et al*[63], who documented a higher odd of hypertension of 1.58 times in psoriatics compared to general population. Moreover, hypertension and psoriasis severity were positively correlated with a hazard ratio (HR) of 1.17 in patients with severe psoriasis and HR of 1.07 in those with mild psoriasis. PsA patients showed an higher odds ratio of 2.07 compared to patients with only psoriasis.

The increased detection of hypertension in psoriatic patients could explain the increased risk of atrial fibrillation in this population. Atrial fibrillation is one of the most frequent cardiac arrhythmia accounting in 0.4%-1% of general population and strictly linking to cardiovascular morbidity and mortality[64].

Emerging data have focused on the potential association between psoriasis and atrial fibrillation documenting that psoriasis may be independently associated with a higher risk of new onset atrial fibrillation[64].

A Danish nationwide cohort study evaluated 36765 mild psoriasis patients and 2793 severe psoriasis patients *vs* 4478926 controls: an increased risk of atrial fibrillation had been found in psoriatics with a direct correlation with skin disease severity. Furthermore, a strong association between atrial fibrillation and early onset psoriasis had emerged[65].

Conversely, Armstrong *et al*[66]had considered a cohort of 2078 psoriatic patients matched to 6234 healthy subjects and had evidenced no statistically significant difference in a 5-year atrial fibrillation incidence between the two groups (2.5% *vs* 3.3% respectively) and no association between incident atrial fibrillation and psoriasis severity.

**PSORIASIS, NAFLD AND CVD: A COMMON INFLAMMATORY PROCESS**

Psoriasis, NAFLD and CVD are considered multifactorial and multi-steps diseases with not completely fully elucidated interactions between genetic, immunological and environmental factors[67,68].

Psoriasis is an immune-mediated disorder sustained and maintained by a Th1-Th17-Th22 cell immune response. The Th1-Th17-Th22 downstream pro-inflammatory cytokines contribute to create a cytokine milieu participating to a systemic chronic inflammation[69,70].

In fact, the low-grade chronic inflammatory process seems to represent the major component linking psoriasis to its comorbidities and leading to insulin resistance, to dysmetabolic profile and to ED and thus predisposing psoriatic patients to atherosclerosis and higher cardiovascular risk[2,4].

Both innate and adaptive immunity participate to physio-pathologic mechanism underlying psoriasis and atherosclerosis. Flammer *et al*[71] in 2012 have interestingly proposed the concept of “two plaques for one syndrome”. In fact, the development of both psoriatic and atherosclerotic plaque is strictly dependent from T cells, monocytes, macrophages and pro-inflammatory cytokines. It is know that a Th1 hyperactivity and the overexpression of Th1-related cytokines represent the basis for the ED being associated with atherosclerotic plaque instability and with an increased risk of athero-thrombotic events[71-74].

Most of inflammatory cytokines are produced by the adipose tissue[75,76] (Table 1). It is known that the adipose tissue is a real endocrine organ able to synthetize adipocytokines, bioactive molecules deeply involved in the inflammation and in the development of Mets and Mets’ components, as dyslipidemia and insulin resistance[75,76].

Among Th1 pro-inflammatory cytokines, TNF-alpha is considered one of the most representative cytokine in psoriasis: Elevated serum levels of TNF-alpha has been detected in psoriatics with a positive correlation with disease severity[77] (Table 1).

In psoriasis, TNF-alpha promotes keratinocyte proliferation, pro-inflammatory cytokines’ production, expression of vascular endothelial cell adhesion molecules and angiogenesis[78].

Although the role of TNF-alpha in the pathogenesis of atherosclerosis remains not completely elucidated, it seems to increase the LDL transcytosis across endothelial cells and to facilitate LDL retention in vascular walls[79] (Table 1).

Furthermore, TNF-alpha interferes with insulin metabolism reducing the auto-phosphorylation of tyrosine residues of insulin receptor and phosphorylation of insulin receptor substrate 1 (IRS-1) thus contributing to the first hit of NAFLD[80] (Table 1).

IL-1 is another important pro-inflammatory cytokine exerting both autocrine and paracrine effects on keratinocytes, lymphocytes and vascular endothelium. In particular, it stimulates the synthesis of inflammatory cardiovascular mediators as IL-6, fibrinogen, C-reactive protein, and increases the expression of adhesion molecules ICAM and VCAM-1 by dermal endothelial cell, leading to the skin recruitment of immune cells[81] (Table 1).

Human atherosclerotic plaques show elevated levels of IL-1β mRNA. This element could suggest that the synthesis of growth factors and other cytokines leading to local inflammatory cascades may be activated by locally synthesized IL-1 protein[82] (Table 1).

IL-1 also participates to pancreatic β-cells’ activity by stimulating the mitogen-activated protein kinases (MAPK) and extracellular signal-regulated kinase (ERK), by affecting the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and by activating the inducible nitric oxide synthase (iNOS)[83].

IL-6 is an inflammatory cytokine which amplifies inflammatory responses by synergizing with other pro-inflammatory cytokines, as TNF-alpha, IL-1 and IL-17. IL-6 is responsible for dermal and epidermal cells’ growth and differentiation and for T cell migration into the epidermis[84] (Table 1).

Although the role of IL-6 is contradictory in NAFLD, recent data have evidenced that it may suppress hepatic cytokine signaling-3 leading to insulin resistance[85] (Table 1).

In addition to the above cytokines, adipose tissue produces leptin, adiponectin, resistin and visfatin, which are impaired in psoriasis and NAFLD and contribute to the ED [86].

ED is considered an early manifestation of vascular alterations which precede the development of hypertension and atherosclerosis in obese[86].

In psoriasis, increased serum levels of leptin, resistin and visfatin and reduced serum levels of adiponectin have been detected[7].

Leptin is a pro-inflammatory adipocytokine which interacts with its specific receptor on endothelial cells leading to the activation of JAK-2/IRS-2/PI3-K/Akt pathways and nuclear translocation of STAT proteins (signal transducer and activator of transcription)[87].

Moreover, leptin is considered a pro-atherogenic factor by promoting vascular smooth muscle cells’ migration and proliferation and by stimulating the synthesis of TNF-alpha with the consequent amplification of inflammatory TNF-alpha related pathways. Recently, hyperleptinemia has been found as a possible risk factor for acute myocardial infarction[88,89] (Table 1).

Resistin seems to support atherosclerosis by favoring ED, vascular smooth muscle cell proliferation, arterial inflammation and foam cells formation. Resistin serum levels resulted higher in patients with acute myocardial infarction compared to patients with stable angina. As other pro-inflammatory adipocytokine, resistin may be involved in the pathogenesis of MetS in psoriatic patients, despite its role in NAFLD remains uncertain[90,91] (Table 1).

Adiponectin is an anti-inflammatory adipocytokine that increases nitric oxide production in endothelial cells by the activation of phosphotidylinositol-3 (PI-3) kinase/Akt signalling pathway. The adiponectin serum level appears reduced both in psoriasis and NAFLD and it may be associated to the decreased endothelial production of NO, which is in turn considered a marker of ED [87,91] (Table 1).

Visfatin is pro-inflammatory adipocytokine contributing to insulin-resistance and to atherosclerotic plaque destabilization. Visfatin serum levels had been found higher in patients with ischemic cerebrovascular disease and myocardial infarction[92,93] (Table 1).

Th17 are implied in the pathogenesis of psoriasis and of other immune-mediated inflammatory diseases by modulating immune cell trafficking and initiating inflammation and cytokines’ production[94].

Th17 had been found overexpressed both in psoriatics’ serum and plaque with a positive correlation with disease severity: IL-17A levels resulted significantly higher in moderate-to severe psoriasis than in mild psoriasis[95,96] (Table 1).

Although the precise role of Th17 in atherosclerosis remains controversial, recent data have hypothesized a putative role in the atherosclerotic plaque vulnerability, which represents the initial step to plaque rupture leading to vessel occlusion, myocardial infarction and stroke. In fact, an increased expression of IL-17A had been observed in human carotid artery plaques of symptomatic patients with stroke or transient ischemic attack[97] (Table 1).

In mice, Th17 and IL-17 may be implicated in the progression from steatosis to steatohepatitis[98] (Table 1).

Angiogenesis is a physio-pathologic process characterized by the new blood vessels’ formation from the pre-existing vasculature and appears important in inflammatory, autoimmune and neoplastic diseases. Therefore, angiogenesis may represent a further link between psoriasis and psoriasis-related comorbidities[99].

Vascular endothelial growth factor (VEGF) is the pivotal angiogenic factor participating to the regulation of metabolism, gene expression, cell proliferation, migration, and survival[100] (Table 1).

VEGF participates to psoriasis’ pathogenesis either in an autocrine manner by directly stimulating keratinocytes’ proliferation and in a paracrine manner by inducing angiogenesis and by providing the fundamental elements to support epidermal proliferation. VEGF results upregulated in serum and lesional psoriatic skin with a correlation with disease severity[101] (Table 1).

As regards NAFLD, Coulon *et al*[102] tested the TNF-alpha, IL-6 and VEGF serum concentrations in an obese population with NAFLD emphasizing higher levels than controls thus indicating the role of pro-inflammatory and pro-angiogenic factors in this pathology.

This aspect appears relevant: in fact, angiogenesis participates to the microvascular changes which are implicated in the hepatic disease progression from fibrosis to cirrhosis[103].

A further mechanism shared by psoriasis, NAFLD and CVD may be the oxidative stress. Oxidative stress results from a disequilibrium between the reduced antioxidant systems and abnormal excessive production of reactive oxygen species (ROS) or reactive nitrogen species (RNS). ROS are produced mainly by mytochondria and their production is regulated by the redox state of the respiratory chain[104,105].

The pathogenesis and the progression of psoriasis is strictly linked to the redox sensitive -cellular signaling pathways, as mitogen-activated protein kinase/activator protein 1 (MAPK/AP1), nuclear factor kappa B (NFkB), and Janus kinase-signal transducers (JAK) and transcription’s activators[106].

Many studies have been conducted aiming the role of oxidative stress in psoriasis and have evidenced that psoriatics show an unbalance between biomarkers of oxidative stress and the antioxidant system. Ferretti *et al*[107] have shown an impairment of oxidant/antioxidant system: Significantly higher serum levels of lipoprotein a [Lp(a)] and lipid hydroperoxides have been found in psoriatics compared to controls. Conversely, paraoxonase-1 (PON1), an anti-inflammatory and anti-oxidant enzyme, had resulted lower than healthy subjects. A positive correlation was found between serum levels of Lp(a), markers of lipid peroxidation and the severity of the disease whereas PON1 activity and Lp(a) were negatively correlated[107,108].

Emre *et al*[109] have investigated the relation between oxidative status and smoking in psoriasis demonstrating the increased serum levels of triglycerides and reduced levels of HDL cholesterol and arylesterase activity in smoker compared to non-smokers psoriatic patients. Therefore, smoking could be considered a risk factor in the progression of psoriasis severity by increasing oxidative stress and thus predisposing psoriatic patients to an higher risk of cardiovascular comorbidities.

A reduction in total antioxidant capacity and in antioxidant vitamins A and E has been found by Rocha-Pereira *et al*[110], who had also confirmed a pro-atherogenic lipid profile in psoriatic patients with an increase of cholesterol, triglycerides, low density lipoprotein cholesterol (LDL), very low density lipoprotein cholesterol (VLDL), apolipoprotein B (apo B), Lp(a) and lipoperoxidation products. These data tend to underline an increased cardiovascular risk in psoriatic patients, particularly in those with severe disease.

It is known that oxidative stress participates to the second hit of the pathogenesis of NAFLD and it may be implicated in the NAFLD progression by interfering with normal cell division. In murine models, alterations of the polyploidization process was found in fatty liver with a large proportion of highly polyploid mononuclear cells, only rarely observed in normal hepatic parenchyma. Moreover, in humans, alterations in hepatocyte ploidy has been documented in liver biopsies from patients with NASH[111].

Oxidative stress participates to the mild chronic vascular inflammation in CVD. In fact, oxygen metabolites are able to interfere with LDL metabolism promoting the formation of oxidized low-density lipoprotein (Ox-LDL), which plays a representative role in atherosclerotic plaque development and in endothelial damage favoring inflammatory vascular cell infiltration[112,113] (Figure 1).

**EFFECTS OF TNF-ALPHA INHIBITORS AND CONVENTIONAL PSORIATIC THERAPIES ON NAFLD AND ON CARDIOVASCULAR RISK FACTORS**

As seen above, the inflammatory process represents the mainstay linking the pathogenesis of psoriasis, of NAFLD and of CVD. Therefore, anti-inflammatory drugs may represent important therapeutic options in the treatment and prevention of these pathologies. Data on literature on the effect of both conventional and biological psoriatic therapies have shown discordant result on their possible action on NAFLD and cardiovascular risk factors[114].

Conventional treatments for moderate to severe psoriasis include cyclosporine A, methotrexate and retinoids. Although effective, their safety profile should be evaluated in their long-term use also considering psoriasis-related comorbidities[115].

In fact, it is well known that methotrexate can mediate liver toxicity and patients with liver dysfunction, as NAFLD/NASH patients, could present an impaired drug metabolism with consequent liver accumulation and an increased susceptibility to liver toxicity[116].

Methotrexate exerts opposite effects on cardiovascular risk in psoriatic patients. In 1989, *Refsum et al*[117] had investigated the effect of methotrexate 25 mg weekly on plasma homocysteine levels showing a significant and transient increase within 48 h after administration.

Conversely, a lower risk of CVD had been found in psoriatic patient treated with MTX compared to patients without MTX[118].

Elevated serum levels of cholesterol and tryglicerides can occur during treatment with retinoids and cyclosporine, although no evidence of an increased cardiovascular risk has been stated with long-term used of etetrinate[118,119].

Moreover, as demonstrated in a prospective non-randomized study on patients affected by PsA, cyclosporine has been associated to a significant elevation of blood pressure values[119].

TNF-alpha inhibitors, IL12/23 inhibitors and IL-17 inhibitors represent three new classes of drugs used in moderate to severe psoriasis with a good efficacy and safety profile. Among biologics, TNF-alpha blockers’ metabolic effect are most widely studied[120,121].

A cross-sectional study had evaluated epicardial fat thickness (EAT), an emerging marker of cardiometabolic risk, on patients with rheumatoid arthritis (RA) treated with TNF-alpha inhibitors compared to RA patients treated with non-biological disease-modifying anti-rheumatic drugs (DMARDs). A significantly lower EAT thickness had been detected in patients treated with TNF-alpha inhibitors than those treated with DMARDs (8.56 ± 1.90mm and 9.71 ± 1.45 mm respectively)[122].

Jókai *et al*[123] had evaluated the positive effect of TNF-alpha inhibitors on carotid and brachial intima-media thickness in patients with psoriasis.

Although dates are few, TNF-alpha blockers seem to act on lipid and glucose metabolism by exerting a potential action on cardiovascular risk factors. It has been evidenced an improvement of insulin-sensitivity in psoriatic patients treated with Etanercept and Infliximab[124,125].

Conversely, long-term use of TNF-alpha inhibitors in patients with rheumatoid arthritis seem not influence insulin resistance parameters[126].

As concern lipid profile, although no statistically significant, raised values of total cholesterol, LDL-C and triglycerides had been found after 24 wk of treatment with Etanercept in psoriatic patients[127].

Adipocytokines’ levels and fat distribution had been assessed in patients with RA and ankylosing spondilitis during long-term treatment with TNF-alpha blockers. A fat mass gain with a tendency to visceral fat accumulation, a reduction of resistin serum levels and no significant modification in leptin, total adiponectin and visfatin serum levels had been evidenced[128]. Another recent study had focused on the influence of TNF-alpha inhibitors on serum levels of adypocitokines showing a partial rebalancing between pro- and anti-inflammatory adypocitokines after 24 wk of anti-TNF-alpha treatment with a reduction of leptin, visfatin and resistin and a mild adiponectin increase[76].

As regards body weight, a body weight increment has been identified after six-months treatment with Etanercept compared to psoriatic patients in treatment with methotrexate[129].

These data had been confirmed by Campanati *et al*[24] who showed a waist-hip-ratio and a BMI increase during treatment with Etanercept. The authors documented a possible preventive effect of Etanercept on liver fibrosis, evidencing a significant reduction of AST/ALT ratio and an improvement of insulin-sensitivity parameters. These elements confirm the strong relation between the alteration of glucose metabolism and NAFLD[24].

Although further larger studies are needed to confirm these data, this hypothetic preventive role may be linked to TNF-alpha inhibitors’ anti-inflammatory properties and action on glucose homeostasis[24].

The favorable effect of TNF-alpha blockers on the risk of MI has been identified in a retrospective study monitoring patients affected by only psoriasis, by only PsA and patients affected by both psoriasis and PsA. Patients with only psoriasis had a significant MI risk reduction (HR, 0.26; 95%CI: 0.12-0.56) whereas non-significant MI risk reduction had been detected in those with only PsA (HR, 0.86; 95%CI: 0.28-2.70) and in those with both psoriasis and PsA. The duration of TNF-alpha inhibitors’ treatment did not seem influence the risk of MI[130,131].

**CONCLUSION**

Psoriasis is a complex and already partially unknown disease whose skin manifestations represent only the edge of an iceberg, which is widely submerged and unknown. Psoriasis and psoriasis-related comorbidities significantly impact on patient’s health and quality of life and negatively interfere in physical-psychic well-being with important repercussion in working daily life. As a multi-organ pathology, psoriasis needs of a multidisciplinary approach and clinicians should evaluate this holistic vision in order to promptly identify and manage psoriasis-related comorbidities influencing patients’ morbidity and mortality. The underlying inflammatory process is the lait motif shared by psoriasis, NAFLD and CVD and overlaps both the common genetic predisposition and modifiable risk factors, as sedentary lifestyle, smoking and alcohol consumption.

Therefore, the therapeutic strategy for psoriasis should be multifaceted and should specifically tailor outcome tools and disease-related items by a patient-based evaluation and by selectively verifying the risk/benefit of each single therapeutic option.

**REFERENCES**

1 **Griffiths CE**, Barker JN. Pathogenesis and clinical features of psoriasis. *Lancet* 2007; **370**: 263-271 [PMID: 17658397]

2 **Boehncke WH**, Boehncke S. More than skin-deep: the many dimensions of the psoriatic disease. *Swiss Med Wkly* 2014; **144**: w13968 [PMID: 24764145 DOI: 10.4414/smw.2014.13968]

3 **Campanati A**, Orciani M, Gorbi S, Regoli F, Di Primio R, Offidani A. Effect of biologic therapies targeting tumour necrosis factor-α on cutaneous mesenchymal stem cells in psoriasis. *Br J Dermatol* 2012; **167**: 68-76 [PMID: 22356229 DOI: 10.1111/j.1365-2133.2012.10900.x]

4 **Ryan C**, Kirby B. Psoriasis is a systemic disease with multiple cardiovascular and metabolic comorbidities. *Dermatol Clin* 2015; **33**: 41-55 [PMID: 25412782 DOI: 10.1016/j.det.2014.09.004]

5 **Ni C**, Chiu MW. Psoriasis and comorbidities: links and risks. *Clin Cosmet Investig Dermatol* 2014; **7**: 119-132 [PMID: 24790463 DOI: 10.2147/CCID.S44843]

6 **Sales R**, Torres T. Psoriasis and metabolic syndrome. *Acta Dermatovenerol Croat* 2014; **22**: 169-174 [PMID: 25230056]

7 **Ganzetti G**, Campanati A, Offidani A. Non-alcoholic fatty liver disease and psoriasis: So far, so near. *World J Hepatol* 2015; **7**: 315-326 [PMID: 25848461 DOI: 10.4254/wjh.v7.i3.315]

8 **Zhang T**, Zhang C, Zhang Y, Tang F, Li H, Zhang Q, Lin H, Wu S, Liu Y, Xue F. Metabolic syndrome and its components as predictors of nonalcoholic fatty liver disease in a northern urban Han Chinese population: a prospective cohort study. *Atherosclerosis* 2015; **240**: 144-148 [PMID: 25785362 DOI: 10.1016/j.atherosclerosis.2015.02.049]

9 **Kotronen A**, Yki-Järvinen H. Fatty liver: a novel component of the metabolic syndrome. *Arterioscler Thromb Vasc Biol* 2008; **28**: 27-38 [PMID: 17690317]

10 **Ozturk K**, Uygun A, Guler AK, Demirci H, Ozdemir C, Cakir M, Sakin YS, Turker T, Sari S, Demirbas S, Karslıoğlu Y, Saglam M. Nonalcoholic fatty liver disease is an independent risk factor for atherosclerosis in young adult men. *Atherosclerosis* 2015; **240**: 380-386 [PMID: 25875390 DOI: 10.1016/j.atherosclerosis.2015.04.009]

11 **Chung GE**, Choi SY, Kim D, Kwak MS, Park HE, Kim MK, Yim JY. Nonalcoholic fatty liver disease as a risk factor of arterial stiffness measured by the cardioankle vascular index. *Medicine* (Baltimore) 2015; **94**: e654 [PMID: 25816034 DOI: 10.1097/MD.0000000000000654]

12 **Gisondi P**, Tessari G, Conti A, Piaserico S, Schianchi S, Peserico A, Giannetti A, Girolomoni G. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. *Br J Dermatol* 2007; **157**: 68-73 [PMID: 17553036]

13 **Armstrong AW**, Harskamp CT, Armstrong EJ. Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies. *J Am Acad Dermatol* 2013; **68**: 654-662 [PMID: 23360868 DOI: 10.1016/j.jaad.2012.08.015]

14 **Ford ES**, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. *JAMA* 2002; **287**: 356-359 [PMID: 11790215]

15 **Hu G**, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. *Arch Intern Med* 2004; **164**: 1066-1076 [PMID: 15159263]

16 **Zindancı I**, Albayrak O, Kavala M, Kocaturk E, Can B, Sudogan S, Koç M. Prevalence of metabolic syndrome in patients with psoriasis. *ScientificWorldJournal* 2012; **2012**: 312463 [PMID: 22654590 DOI: 10.1100/2012/312463]

17 **Mallbris L**, Ritchlin CT, Ståhle M. Metabolic disorders in patients with psoriasis and psoriatic arthritis. *Curr Rheumatol Rep* 2006; **8**: 355-363 [PMID: 16973109]

18 **Neimann AL**, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM. Prevalence of cardiovascular risk factors in patients with psoriasis. *J Am Acad Dermatol* 2006; **55**: 829-835 [PMID: 17052489]

19 **Sommer DM**, Jenisch S, Suchan M, Christophers E, Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. *Arch Dermatol Res* 2006; **298**: 321-328 [PMID: 17021763]

20 **Adams LA**, Angulo P, Lindor KD. Nonalcoholic fatty liver disease. *CMAJ* 2005; **172**: 899-905 [PMID: 15795412]

21 **Roberts KK**, Cochet AE, Lamb PB, Brown PJ, Battafarano DF, Brunt EM, Harrison SA. The prevalence of NAFLD and NASH among patients with psoriasis in a tertiary care dermatology and rheumatology clinic. *Aliment Pharmacol Ther* 2015; **41**: 293-300 [PMID: 25521607 DOI: 10.1111/apt.13042]

22 **van der Voort EA**, Koehler EM, Dowlatshahi EA, Hofman A, Stricker BH, Janssen HL, Schouten JN, Nijsten T. Psoriasis is independently associated with nonalcoholic fatty liver disease in patients 55 years old or older: Results from a population-based study. *J Am Acad Dermatol* 2014; **70**: 517-524 [PMID: 24373781 DOI: 10.1016/j.jaad.2013.10.044]

23 **Candia R**, Ruiz A, Torres-Robles R, Chávez-Tapia N, Méndez-Sánchez N, Arrese M. Risk of non-alcoholic fatty liver disease in patients with psoriasis: a systematic review and meta-analysis. *J Eur Acad Dermatol Venereol* 2015; **29**: 656-662 [PMID: 25418531 DOI: 10.1111/jdv.12847]

24 **Campanati A**, Ganzetti G, Di Sario A, Damiani A, Sandroni L, Rosa L, Benedetti A, Offidani A. The effect of etanercept on hepatic fibrosis risk in patients with non-alcoholic fatty liver disease, metabolic syndrome, and psoriasis. *J Gastroenterol* 2013; **48**: 839-846 [PMID: 23065020 DOI: 10.1007/s00535-012-0678-9]

25 **Lee YA**, Kang SG, Song SW, Rho JS, Kim EK. Association between metabolic syndrome, smoking status and coronary artery calcification. *PLoS One* 2015; **10**: e0122430 [PMID: 25816100 DOI: 10.1371/journal.pone.0122430]

26 **Cohen JB**, Cohen DL. Cardiovascular and renal effects of weight reduction in obesity and the metabolic syndrome. *Curr Hypertens Rep* 2015; **17**: 34 [PMID: 25833456 DOI: 10.1007/s11906-015-0544-2]

27 **van Vliet-Ostaptchouk JV**, Nuotio ML, Slagter SN, Doiron D, Fischer K, Foco L, Gaye A, Gögele M, Heier M, Hiekkalinna T, Joensuu A, Newby C, Pang C, Partinen E, Reischl E, Schwienbacher C, Tammesoo ML, Swertz MA, Burton P, Ferretti V, Fortier I, Giepmans L, Harris JR, Hillege HL, Holmen J, Jula A, Kootstra-Ros JE, Kvaløy K, Holmen TL, Männistö S, Metspalu A, Midthjell K, Murtagh MJ, Peters A, Pramstaller PP, Saaristo T, Salomaa V, Stolk RP, Uusitupa M, van der Harst P, van der Klauw MM, Waldenberger M, Perola M, Wolffenbuttel BH. The prevalence of metabolic syndrome and metabolically healthy obesity in Europe: a collaborative analysis of ten large cohort studies. *BMC Endocr Disord* 2014; **14**: 9 [PMID: 24484869 DOI: 10.1186/1472-6823-14-9]

28 **Gutmark-Little I**, Shah KN. Obesity and the metabolic syndrome in pediatric psoriasis. *Clin Dermatol* 2015; **33**: 305-315 [PMID: 25889131 DOI: 10.1016/j.clindermatol.2014.12.006]

29 **Danielsen K**, Wilsgaard T, Olsen AO, Eggen AE, Olsen K, Cassano PA, Furberg AS. Elevated odds of metabolic syndrome in psoriasis: a population-based study of age and sex differences. *Br J Dermatol* 2015; **172**: 419-427 [PMID: 25059341 DOI: 10.1111/bjd.13288]

30 **Carrascosa JM**, Rocamora V, Fernandez-Torres RM, Jimenez-Puya R, Moreno JC, Coll-Puigserver N, Fonseca E. Obesity and psoriasis: inflammatory nature of obesity, relationship between psoriasis and obesity, and therapeutic implications. *Actas Dermosifiliogr* 2014; **105**: 31-44 [PMID: 23177976 DOI: 10.1016/j.ad.2012.08.003]

31 **Ma C**, Schupp CW, Armstrong EJ, Armstrong AW. Psoriasis and dyslipidemia: a population-based study analyzing the National Health and Nutrition Examination Survey (NHANES). *J Eur Acad Dermatol Venereol* 2014; **28**: 1109-1112 [PMID: 23909936 DOI: 10.1111/jdv.12232]

32 **Offidani AM**, Ferretti G, Taus M, Simonetti O, Dousset N, Valdiguie P, Curatola G, Bossi G. Lipoprotein peroxidation in adult psoriatic patients. *Acta Derm Venereol Suppl* (Stockh) 1994; **186**: 38-40 [PMID: 8073834]

33 **Driessen RJ**, Boezeman JB, Van De Kerkhof PC, De Jong EM. Cardiovascular risk factors in high-need psoriasis patients and its implications for biological therapies. *J Dermatolog Treat* 2009; **20**: 42-47 [PMID: 18649164 DOI: 10.1080/09546630802225702]

34 **Cohen AD**, Gilutz H, Henkin Y, Zahger D, Shapiro J, Bonneh DY, Vardy DA. Psoriasis and the metabolic syndrome. *Acta Derm Venereol* 2007; **87**: 506-509 [PMID: 17989888]

35 **Al-Mutairi N**, Al-Farag S, Al-Mutairi A, Al-Shiltawy M. Comorbidities associated with psoriasis: an experience from the Middle East. *J Dermatol* 2010; **37**: 146-155 [PMID: 20175849 DOI: 10.1111/j.1346-8138.2009.00777.x]

36 **Langan SM**, Seminara NM, Shin DB, Troxel AB, Kimmel SE, Mehta NN, Margolis DJ, Gelfand JM. Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. *J Invest Dermatol* 2012; **132**: 556-562 [PMID: 22113483 DOI: 10.1038/jid.2011.365]

37 **Aguilar D**, Fernandez ML. Hypercholesterolemia induces adipose dysfunction in conditions of obesity and nonobesity. *Adv Nutr* 2014; **5**: 497-502 [PMID: 25469381]

38 **Gelfand JM**, Mehta NN, Langan SM. Psoriasis and cardiovascular risk: strength in numbers, part II. *J Invest Dermatol* 2011; **131**: 1007-1010 [PMID: 21494241 DOI: 10.1038/jid.2011.32]

39 **Torres T**, Bettencourt N. Psoriasis: the visible killer. *Rev Port Cardiol* 2014; **33**: 95-99 [PMID: 24525359 DOI: 10.1016/j.repc.2013.06.017]

40 **Maradit-Kremers H**, Icen M, Ernste FC, Dierkhising RA, McEvoy MT. Disease severity and therapy as predictors of cardiovascular risk in psoriasis: a population-based cohort study. *J Eur Acad Dermatol Venereol* 2012; **26**: 336-343 [PMID: 22339785 DOI: 10.1111/j.1468-3083.2011.04071.x]

41 **Gelfand JM**, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. *JAMA* 2006; **296**: 1735-1741 [PMID: 17032986]

42 **Brauchli YB**, Jick SS, Miret M, Meier CR. Psoriasis and risk of incident myocardial infarction, stroke or transient ischaemic attack: an inception cohort study with a nested case-control analysis. *Br J Dermatol* 2009; **160**: 1048-1056 [PMID: 19210501 DOI: 10.1111/j.1365-2133.2008.09020.x]

43 **Li WQ**, Han JL, Manson JE, Rimm EB, Rexrode KM, Curhan GC, Qureshi AA. Psoriasis and risk of nonfatal cardiovascular disease in U.S. women: a cohort study. *Br J Dermatol* 2012; **166**: 811-818 [PMID: 22175820 DOI: 10.1111/j.1365-2133.2011.10774.x]

44 **Ernste FC**, Sánchez-Menéndez M, Wilton KM, Crowson CS, Matteson EL, Maradit Kremers H. Cardiovascular risk profile at the onset of psoriatic arthritis: a population-based cohort study. *Arthritis Care Res* (Hoboken) 2015; **67**: 1015-1021 [PMID: 25581120 DOI: 10.1002/acr.22536]

45 **Favarato MH**, Mease P, Gonçalves CR, Gonçalves Saad C, Sampaio-Barros PD, Goldenstein-Schainberg C. Hypertension and diabetes significantly enhance the risk of cardiovascular disease in patients with psoriatic arthritis. *Clin Exp Rheumatol* 2014; **32**: 182-187 [PMID: 24480317]

46 **Yiu KH**, Yeung CK, Zhao CT, Chan JC, Siu CW, Tam S, Wong CS, Yan GH, Yue WS, Khong PL, Chan HH, Tse HF. Prevalence and extent of subclinical atherosclerosis in patients with psoriasis. *J Intern Med* 2013; **273**: 273-282 [PMID: 23003220 DOI: 10.1111/joim.12002]

47 **Balci DD**, Balci A, Karazincir S, Ucar E, Iyigun U, Yalcin F, Seyfeli E, Inandi T, Egilmez E. Increased carotid artery intima-media thickness and impaired endothelial function in psoriasis. *J Eur Acad Dermatol Venereol* 2009; **23**: 1-6 [PMID: 18702627 DOI: 10.1111/j.1468-3083.2008.02936.x]

48 **Mintz GS**. Intravascular imaging of coronary calcification and its clinical implications. *JACC Cardiovasc Imaging* 2015; **8**: 461-471 [PMID: 25882575 DOI: 10.1016/j.jcmg.2015.02.003]

49 **Seremet S**, Genc B, Tastan A, Akyildiz ZI, Nazli C, Ozcelik S, Afsar FS, Solak A, Emren V. Are all patients with psoriasis at increased risk for coronary artery disease? *Int J Dermatol* 2015; **54**: 355-361 [PMID: 25428719 DOI: 10.1111/ijd.12673]

50 **Staniak HL**, Bittencourt MS, de Souza Santos I, Sharovsky R, Sabbag C, Goulart AC, Lotufo PA, Benseñor IM. Association between psoriasis and coronary calcium score. *Atherosclerosis* 2014; **237**: 847-852 [PMID: 25463132 DOI: 10.1016/j.atherosclerosis.2014.11.004]

51 **Mahiques-Santos L**, Soriano-Navarro CJ, Perez-Pastor G, Tomas-Cabedo G, Pitarch-Bort G, Valcuende-Cavero F. Psoriasis and ischemic coronary artery disease. *Actas Dermosifiliogr* 2015; **106**: 112-116 [PMID: 25304822 DOI: 10.1016/j.ad.2014.08.002]

52 **Gullu H**, Caliskan M, Dursun R, Ciftci O, Guven A, Muderrisoglu H. Impaired coronary microvascular function and its association with disease duration and inflammation in patients with psoriasis. *Echocardiography* 2013; **30**: 912-918 [PMID: 23488894 DOI: 10.1111/echo.12156]

53 **Ikonomidis I**, Makavos G, Papadavid E, Varoudi M, Andreadou I, Gravanis K, Theodoropoulos K, Pavlidis G, Triantafyllidi H, Parissis J, Paraskevaidis I, Rigopoulos D, Lekakis J. Similarities in coronary function and myocardial deformation between psoriasis and coronary artery disease: the role of oxidative stress and inflammation. *Can J Cardiol* 2015; **31**: 287-295 [PMID: 25660150 DOI: 10.1016/j.cjca.2014.11.002]

54 **Lee SJ**, Lee DG, Lim DS, Hong S, Park JS. Difference in the prognostic significance of N-terminal pro-B-type natriuretic peptide between cardioembolic and noncardioembolic ischemic strokes. *Dis Markers* 2015; **2015**: 597570 [PMID: 25834300 DOI: 10.1155/2015/597570]

55 **Pietrzak A**, Bartosinska J, Blaszczyk R, Chodorowska G, Brzozowski W, Hercogova J, Donica H, Lotti T. Increased serum level of N-terminal Pro-B-type natriuretic peptide as a possible biomarker of cardiovascular risk in psoriatic patients. *J Eur Acad Dermatol Venereol* 2015; **29**: 1010-1014 [PMID: 24735175 DOI: 10.1111/jdv.12528]

56 **Biyik I**, Narin A, Bozok MA, Ergene O. Echocardiographic and clinical abnormalities in patients with psoriasis. *J Int Med Res* 2006; **34**: 632-639 [PMID: 17294995]

57 **Bilgiç Ö**, Altınyazar HC, Baran H, Ünlü A. Serum homocysteine, asymmetric dimethyl arginine (ADMA) and other arginine-NO pathway metabolite levels in patients with psoriasis. *Arch Dermatol Res* 2015; **307**: 439-444 [PMID: 25708188]

58 **Giannoni M**, Consales V, Campanati A, Ganzetti G, Giuliodori K, Postacchini V, Liberati G, Azzaretto L, Vichi S, Guanciarossa F, Offidani A. Homocysteine plasma levels in psoriasis patients: our experience and review of the literature. *J Eur Acad Dermatol Venereol* 2015; **29**: 1781-1785 [PMID: 25809089 DOI: 10.1111/jdv.13023]

59 **Erturan I**, Köroğlu BK, Adiloğlu A, Ceyhan AM, Akkaya VB, Tamer N, Başak PY, Korkmaz S, Ersoy IH, Kilinç O. Evaluation of serum sCD40L and homocysteine levels with subclinical atherosclerosis indicators in patients with psoriasis: a pilot study. *Int J Dermatol* 2014; **53**: 503-509 [PMID: 24673360]

60 **Erfan G**, Guzel S, Alpsoy S, Rifaioglu EN, Kaya S, Kucukyalcın V, Topcu B, Kulac M. Serum YKL-40: a potential biomarker for psoriasis or endothelial dysfunction in psoriasis? *Mol Cell Biochem* 2015; **400**: 207-212 [PMID: 25421412 DOI: 10.1007/s11010-014-2277-y]

61 **Łata E**, Gisterek I, Matkowski R, Szelachowska J, Kornafel J. [The importance of determining the prognostic marker YKL-40 in serum and tissues]. *Pol Merkur Lekarski* 2010; **28**: 505-508 [PMID: 20642115]

62 **Ahmed SF**, Attia EA, Saad AA, Sharara M, Fawzy H, El Nahrery EM. Serum YKL-40 in psoriasis with and without arthritis; correlation with disease activity and high-resolution power Doppler ultrasonographic joint findings. *J Eur Acad Dermatol Venereol* 2015; **29**: 682-688 [PMID: 25087779 DOI: 10.1111/jdv.12653]

63 **Armstrong AW**, Harskamp CT, Armstrong EJ. The association between psoriasis and hypertension: a systematic review and meta-analysis of observational studies. *J Hypertens* 2013; **31**: 433-442; discussion 442-443 [PMID: 23249828 DOI: 10.1097/HJH.0b013e32835bcce1]

64 **Zhang Z**, Li G, Liu T. Psoriasis and risk of atrial fibrillation. *Int J Cardiol* 2015; **185**: 301-303 [PMID: 25828669 DOI: 10.1016/j.ijcard.2015.03.149]

65 **Ahlehoff O**, Gislason GH, Jørgensen CH, Lindhardsen J, Charlot M, Olesen JB, Abildstrøm SZ, Skov L, Torp-Pedersen C, Hansen PR. Psoriasis and risk of atrial fibrillation and ischaemic stroke: a Danish Nationwide Cohort Study. *Eur Heart J* 2012; **33**: 2054-2064 [PMID: 21840930 DOI: 10.1093/eurheartj/ehr285]

66 **Armstrong AW**, Azizi S, Wu J, Harskamp CT, Farrow J, Johnson MA, Klem K, Anderson D, Armstrong EJ. Psoriasis, electrocardiographic characteristics, and incidence of atrial fibrillation. *Arch Dermatol Res* 2013; **305**: 891-897 [PMID: 24166719 DOI: 10.1007/s00403-013-1419-5]

67 **Ganzetti G**, Campanati A, Santarelli A, Pozzi V, Molinelli E, Minnetti I, Brisigotti V, Procaccini M, Emanuelli M, Offidani A. Involvement of the oral cavity in psoriasis: results of a clinical study. *Br J Dermatol* 2015; **172**: 282-285 [PMID: 25078556 DOI: 10.1111/bjd.13201]

68 **Kouris A**, Pistiki A, Katoulis A, Georgitsi M, Giatrakou S, Papadavid E, Netea MG, Stavrianeas N, Giamarellos-Bourboulis EJ. Proinflammatory cytokine responses in patients with psoriasis. *Eur Cytokine Netw* 2014; **25**: 63-68 [PMID: 25679113 DOI: 10.1684/ecn.2014.0358]

69 **Boehncke S**, Boehncke WH. 'Upgrading' psoriasis responsibly. *Exp Dermatol* 2014; **23**: 710-711 [PMID: 25040560 DOI: 10.1111/exd.12494]

70 **Mrowietz U**, Steinz K, Gerdes S. Psoriasis: to treat or to manage? *Exp Dermatol* 2014; **23**: 705-709 [PMID: 24815425 DOI: 10.1111/exd.12437]

71 **Hansson GK**. Inflammation, atherosclerosis, and coronary artery disease. *N Engl J Med* 2005; **352**: 1685-1695 [PMID: 15843671]

72 **Nilsson J**, Hansson GK, Shah PK. Immunomodulation of atherosclerosis: implications for vaccine development. *Arterioscler Thromb Vasc Biol* 2005; **25**: 18-28 [PMID: 15514204]

73 **Hansson GK**, Libby P. The immune response in atherosclerosis: a double-edged sword. *Nat Rev Immunol* 2006; **6**: 508-519 [PMID: 16778830]

74 **Flammer AJ**, Ruschitzka F. Psoriasis and atherosclerosis: two plaques, one syndrome? *Eur Heart J* 2012; **33**: 1989-1991 [PMID: 22108835 DOI: 10.1093/eurheartj/ehr425]

75 **Kershaw EE**, Flier JS. Adipose tissue as an endocrine organ. *J Clin Endocrinol Metab* 2004; **89**: 2548-2556 [PMID: 15181022]

76 **Campanati A**, Ganzetti G, Giuliodori K, Marra M, Bonfigli A, Testa R, Offidani A. Serum levels of adipocytokines in psoriasis patients receiving tumor necrosis factor-α inhibitors: results of a retrospective analysis. *Int J Dermatol* 2015; **54**: 839-845 [PMID: 25877149 DOI: 10.1111/ijd.12706]

77 **Pietrzak AT**, Zalewska A, Chodorowska G, Krasowska D, Michalak-Stoma A, Nockowski P, Osemlak P, Paszkowski T, Roliński JM. Cytokines and anticytokines in psoriasis. *Clin Chim Acta* 2008; **394**: 7-21 [PMID: 18445484 DOI: 10.1016/j.cca.2008.04.005]

78 **Hui E**, Xu A, Bo Yang H, Lam KS. Obesity as the common soil of non-alcoholic fatty liver disease and diabetes: Role of adipokines. *J Diabetes Investig* 2013; **4**: 413-425 [PMID: 24843689 DOI: 10.1111/jdi.12093]

79 **Zhang Y**, Yang X, Bian F, Wu P, Xing S, Xu G, Li W, Chi J, Ouyang C, Zheng T, Wu D, Zhang Y, Li Y, Jin S. TNF-α promotes early atherosclerosis by increasing transcytosis of LDL across endothelial cells: crosstalk between NF-κB and PPAR-γ. *J Mol Cell Cardiol* 2014; **72**: 85-94 [PMID: 24594319 DOI: 10.1016/j.yjmcc.2014.02.012]

80 **Gottlieb AB**, Dann F, Menter A. Psoriasis and the metabolic syndrome. *J Drugs Dermatol* 2008; **7**: 563-572 [PMID: 18561588]

81 **Foster AM**, Baliwag J, Chen CS, Guzman AM, Stoll SW, Gudjonsson JE, Ward NL, Johnston A. IL-36 promotes myeloid cell infiltration, activation, and inflammatory activity in skin. *J Immunol* 2014; **192**: 6053-6061 [PMID: 24829417 DOI: 10.4049/jimmunol.1301481]

82 **Matsuura E**, Atzeni F, Sarzi-Puttini P, Turiel M, Lopez LR, Nurmohamed MT. Is atherosclerosis an autoimmune disease? *BMC Med* 2014; **12**: 47 [PMID: 24642015 DOI: 10.1186/1741-7015-12-47]

83 **Cieślak M**, Wojtczak A, Cieślak M. Role of pro-inflammatory cytokines of pancreatic islets and prospects of elaboration of new methods for the diabetes treatment. *Acta Biochim Pol* 2015; **62**: 15-21 [PMID: 25781159]

84 **Wang Y**, Chen J, Zhao Y, Geng L, Song F, Chen HD. Psoriasis is associated with increased levels of serum leptin. *Br J Dermatol* 2008; **158**: 1134-1135 [PMID: 18294316 DOI: 10.1111/j.1365-2133.2008.08456.x]

85 **Pearce SG**, Thosani NC, Pan JJ. Noninvasive biomarkers for the diagnosis of steatohepatitis and advanced fibrosis in NAFLD. *Biomark Res* 2013; **1**: 7 [PMID: 24252302 DOI: 10.1186/2050-7771-1-7]

86 **DeMarco VG**, Aroor AR, Sowers JR. The pathophysiology of hypertension in patients with obesity. *Nat Rev Endocrinol* 2014; **10**: 364-376 [PMID: 24732974 DOI: 10.1038/nrendo.2014.44]

87 **Adya R**, Tan BK, Randeva HS. Differential effects of leptin and adiponectin in endothelial angiogenesis. *J Diabetes Res* 2015; **2015**: 648239 [PMID: 25650072 DOI: 10.1155/2015/648239]

88 **Nalini D**, Karthick R, Shirin V, Manohar G, Malathi R. "Role of the adipocyte hormone leptin in cardiovascular diseases - a study from Chennai based Population". *Thromb J* 2015; **13**: 12 [PMID: 25762868 DOI: 10.1186/s12959-015-0042-4]

89 **Chiu CZ**, Wang BW, Shyu KG. Molecular regulation of the expression of leptin by hypoxia in human coronary artery smooth muscle cells. *J Biomed Sci* 2015; **22**: 5 [PMID: 25573199 DOI: 10.1186/s12929-014-0109-8]

90 **Muse ED**, Feldman DI, Blaha MJ, Dardari ZA, Blumenthal RS, Budoff MJ, Nasir K, Criqui MH, Cushman M, McClelland RL, Allison MA. The association of resistin with cardiovascular disease in the Multi-Ethnic Study of Atherosclerosis. *Atherosclerosis* 2015; **239**: 101-108 [PMID: 25585029 DOI: 10.1016/j.atherosclerosis.2014.12.044]

91 **Ronti T**, Lupattelli G, Mannarino E. The endocrine function of adipose tissue: an update. *Clin Endocrinol* (Oxf) 2006; **64**: 355-365 [PMID: 16584505]

92 **Kong Q**, Xia M, Liang R, Li L, Cu X, Sun Z, Hu J. Increased serum visfatin as a risk factor for atherosclerosis in patients with ischaemic cerebrovascular disease. *Singapore Med J* 2014; **55**: 383-387 [PMID: 25091888]

93 **Mazaherioun M**, Hosseinzadeh-Attar MJ, Janani L, Vasheghani Farahani A, Rezvan N, Karbaschian Z, Hossein-Nezhad A. Elevated serum visfatin levels in patients with acute myocardial infarction. *Arch Iran Med* 2012; **15**: 688-692 [PMID: 23102245]

94 **Golden JB**, McCormick TS, Ward NL. IL-17 in psoriasis: implications for therapy and cardiovascular co-morbidities. *Cytokine* 2013; **62**: 195-201 [PMID: 23562549 DOI: 10.1016/j.cyto.2013.03.013]

95 **Zhang L**, Yang XQ, Cheng J, Hui RS, Gao TW. Increased Th17 cells are accompanied by FoxP3(+) Treg cell accumulation and correlated with psoriasis disease severity. *Clin Immunol* 2010; **135**: 108-117 [PMID: 20006553 DOI: 10.1016/j.clim.2009.11.008]

96 **Kagami S**, Rizzo HL, Lee JJ, Koguchi Y, Blauvelt A. Circulating Th17, Th22, and Th1 cells are increased in psoriasis. *J Invest Dermatol* 2010; **130**: 1373-1383 [PMID: 20032993 DOI: 10.1038/jid.2009.399]

97 **Erbel C**, Akhavanpoor M, Okuyucu D, Wangler S, Dietz A, Zhao L, Stellos K, Little KM, Lasitschka F, Doesch A, Hakimi M, Dengler TJ, Giese T, Blessing E, Katus HA, Gleissner CA. IL-17A influences essential functions of the monocyte/macrophage lineage and is involved in advanced murine and human atherosclerosis. *J Immunol* 2014; **193**: 4344-4355 [PMID: 25261478 DOI: 10.4049/jimmunol.1400181]

98 **Tang Y**, Bian Z, Zhao L, Liu Y, Liang S, Wang Q, Han X, Peng Y, Chen X, Shen L, Qiu D, Li Z, Ma X. Interleukin-17 exacerbates hepatic steatosis and inflammation in non-alcoholic fatty liver disease. *Clin Exp Immunol* 2011; **166**: 281-290 [PMID: 21985374 DOI: 10.1111/j.1365-2249.2011.04471.x]

99 **Campanati A**, Goteri G, Simonetti O, Ganzetti G, Giuliodori K, Giuliano A, Sabato S, Stramazzotti D, Gulini E, Dusi D, De Blasio S, Fabris G, Offidani A. Angiogenesis in psoriatic skin and its modifications after administration of etanercept: videocapillaroscopic, histological and immunohistochemical evaluation. *Int J Immunopathol Pharmacol* 2009; **22**: 371-377 [PMID: 19505391]

100 **Smith GA**, Fearnley GW, Harrison MA, Tomlinson DC, Wheatcroft SB, Ponnambalam S. Vascular endothelial growth factors: multitasking functionality in metabolism, health and disease. *J Inherit Metab Dis* 2015; **38**: 753-763 [PMID: 25868665]

101 **Li W**, Man XY, Chen JQ, Zhou J, Cai SQ, Zheng M. Targeting VEGF/VEGFR in the treatment of psoriasis. *Discov Med* 2014; **18**: 97-104 [PMID: 25227750]

102 **Coulon S**, Francque S, Colle I, Verrijken A, Blomme B, Heindryckx F, De Munter S, Prawitt J, Caron S, Staels B, Van Vlierberghe H, Van Gaal L, Geerts A. Evaluation of inflammatory and angiogenic factors in patients with non-alcoholic fatty liver disease. *Cytokine* 2012; **59**: 442-449 [PMID: 22658783 DOI: 10.1016/j.cyto.2012.05.001]

103 **Coulon S**, Heindryckx F, Geerts A, Van Steenkiste C, Colle I, Van Vlierberghe H. Angiogenesis in chronic liver disease and its complications. *Liver Int* 2011; **31**: 146-162 [PMID: 21073649 DOI: 10.1111/j.1478-3231.2010.02369.x]

104 **Skulachev VP**. Role of uncoupled and non-coupled oxidations in maintenance of safely low levels of oxygen and its one-electron reductants. *Q Rev Biophys* 1996; **29**: 169-202 [PMID: 8870073]

105 **Murphy MP**. How mitochondria produce reactive oxygen species. *Biochem J* 2009; **417**: 1-13 [PMID: 19061483 DOI: 10.1042/BJ20081386]

106 **Zhou Q**, Mrowietz U, Rostami-Yazdi M. Oxidative stress in the pathogenesis of psoriasis. *Free Radic Biol Med* 2009; **47**: 891-905 [PMID: 19577640 DOI: 10.1016/j.freeradbiomed.2009.06.033]

107 **Nemati H**, Khodarahmi R, Sadeghi M, Ebrahimi A, Rezaei M, Vaisi-Raygani A. Antioxidant status in patients with psoriasis. *Cell Biochem Funct* 2014; **32**: 268-273 [PMID: 24895696]

108 **Ferretti G**, Bacchetti T, Campanati A, Simonetti O, Liberati G, Offidani A. Correlation between lipoprotein(a) and lipid peroxidation in psoriasis: role of the enzyme paraoxonase-1. *Br J Dermatol* 2012; **166**: 204-207 [PMID: 21790517 DOI: 10.1111/j.1365-2133.2011.10539.x]

109 **Emre S**, Metin A, Demirseren DD, Kilic S, Isikoglu S, Erel O. The relationship between oxidative stress, smoking and the clinical severity of psoriasis. *J Eur Acad Dermatol Venereol* 2013; **27**: e370-e375 [PMID: 23004342 DOI: 10.1111/j.1468-3083.2012.04700.x]

110 **Rocha-Pereira P**, Santos-Silva A, Rebelo I, Figueiredo A, Quintanilha A, Teixeira F. Dislipidemia and oxidative stress in mild and in severe psoriasis as a risk for cardiovascular disease. *Clin Chim Acta* 2001; **303**: 33-39 [PMID: 11163020]

111 **Gentric G**, Maillet V, Paradis V, Couton D, L'Hermitte A, Panasyuk G, Fromenty B, Celton-Morizur S, Desdouets C. Oxidative stress promotes pathologic polyploidization in nonalcoholic fatty liver disease. *J Clin Invest* 2015; **125**: 981-992 [PMID: 25621497 DOI: 10.1172/JCI73957]

112 **Gradinaru D**, Borsa C, Ionescu C, Prada GI. Oxidized LDL and NO synthesis-Biomarkers of endothelial dysfunction and ageing. *Mech Ageing Dev* 2015; **151**: 101-113 [PMID: 25804383 DOI: 10.1016/j.mad.2015.03.003]

113 **Perrotta I**, Aquila S. The role of oxidative stress and autophagy in atherosclerosis. *Oxid Med Cell Longev* 2015; **2015**: 130315 [PMID: 25866599 DOI: 10.1155/2015/130315]

114 **Grine L**, Dejager L, Libert C, Vandenbroucke RE. An inflammatory triangle in psoriasis: TNF, type I IFNs and IL-17. *Cytokine Growth Factor Rev* 2015; **26**: 25-33 [PMID: 25434285 DOI: 10.1016/j.cytogfr.2014.10.009]

115 **Busard C**, Zweegers J, Limpens J, Langendam M, Spuls PI. Combined use of systemic agents for psoriasis: a systematic review. *JAMA Dermatol* 2014; **150**: 1213-1220 [PMID: 25188393 DOI: 10.1001/jamadermatol.2014.1111]

116 **Hardwick RN**, Clarke JD, Lake AD, Canet MJ, Anumol T, Street SM, Merrell MD, Goedken MJ, Snyder SA, Cherrington NJ. Increased susceptibility to methotrexate-induced toxicity in nonalcoholic steatohepatitis. *Toxicol Sci* 2014; **142**: 45-55 [PMID: 25080921 DOI: 10.1093/toxsci/kfu156]

117 **Refsum H**, Helland S, Ueland PM. Fasting plasma homocysteine as a sensitive parameter of antifolate effect: a study of psoriasis patients receiving low-dose methotrexate treatment. *Clin Pharmacol Ther* 1989; **46**: 510-520 [PMID: 2582708]

118 **Horreau C**, Pouplard C, Brenaut E, Barnetche T, Misery L, Cribier B, Jullien D, Aractingi S, Aubin F, Joly P, Le Maître M, Ortonne JP, Paul C, Richard MA. Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review. *J Eur Acad Dermatol Venereol* 2013; **27** Suppl 3: 12-29 [PMID: 23845149 DOI: 10.1111/jdv.12163]

119 **Mosca S**, Gargiulo P, Balato N, Di Costanzo L, Parente A, Paolillo S, Ayala F, Trimarco B, Crea F, Perrone-Filardi P. Ischemic cardiovascular involvement in psoriasis: a systematic review. *Int J Cardiol* 2015; **178**: 191-199 [PMID: 25464252 DOI: 10.1016/j.ijcard.2014.10.092]

120 **Lebwohl M**. Biologics for psoriasis: a translational research success story. *J Invest Dermatol* 2015; **135**: 1205-1207 [PMID: 25882456 DOI: 10.1038/jid.2014.549]

121 **Campanati A**, Giuliodori K, Ganzetti G, Liberati G, Offidani AM. A patient with psoriasis and vitiligo treated with etanercept. *Am J Clin Dermatol* 2010; **11** Suppl 1: 46-48 [PMID: 20586509 DOI: 10.2165/1153424-S0-000000000-00000]

122 **Lima-Martínez MM**, Campo E, Salazar J, Paoli M, Maldonado I, Acosta C, Rodney M, Contreras M, Cabrera-Rego JO, Iacobellis G. Epicardial fat thickness as cardiovascular risk factor and therapeutic target in patients with rheumatoid arthritis treated with biological and nonbiological therapies. *Arthritis* 2014; **2014**: 782850 [PMID: 25574390 DOI: 10.1155/2014/782850]

123 **Jókai H**, Szakonyi J, Kontár O, Marschalkó M, Szalai K, Kárpáti S, Holló P. Impact of effective tumor necrosis factor-alfa inhibitor treatment on arterial intima-media thickness in psoriasis: results of a pilot study. *J Am Acad Dermatol* 2013; **69**: 523-529 [PMID: 23891393 DOI: 10.1016/j.jaad.2013.06.019]

124 **Puig L**, Strohal R, Fuiman J, Pedersen R, Szumski A, Koenig AS, Robertson D, Drexel H. Cardiometabolic biomarkers in chronic plaque psoriasis before and after etanercept treatment. *J Dermatolog Treat* 2014; **25**: 470-481 [PMID: 24219012 DOI: 10.3109/09546634.2013.848260]

125 **Marra M**, Campanati A, Testa R, Sirolla C, Bonfigli AR, Franceschi C, Marchegiani F, Offidani A. Effect of etanercept on insulin sensitivity in nine patients with psoriasis. *Int J Immunopathol Pharmacol* 2007; **20**: 731-736 [PMID: 18179745]

126 **Ferraz-Amaro I**, Arce-Franco M, Muñiz J, López-Fernández J, Hernández-Hernández V, Franco A, Quevedo J, Martínez-Martín J, Díaz-González F. Systemic blockade of TNF-α does not improve insulin resistance in humans. *Horm Metab Res* 2011; **43**: 801-808 [PMID: 22009376 DOI: 10.1055/s-0031-1287783]

127 **Lestre S**, Diamantino F, Veloso L, Fidalgo A, Ferreira A. Effects of etanercept treatment on lipid profile in patients with moderate-to-severe chronic plaque psoriasis: a retrospective cohort study. *Eur J Dermatol* 2011; **21**: 916-920 [PMID: 21983007 DOI: 10.1684/ejd.2011.1548]

128 **Toussirot É**, Mourot L, Dehecq B, Wendling D, Grandclément É, Dumoulin G. TNFα blockade for inflammatory rheumatic diseases is associated with a significant gain in android fat mass and has varying effects on adipokines: a 2-year prospective study. *Eur J Nutr* 2014; **53**: 951-961 [PMID: 24173963 DOI: 10.1007/s00394-013-0599-2]

129 **Gisondi P**, Cotena C, Tessari G, Girolomoni G. Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study. *J Eur Acad Dermatol Venereol* 2008; **22**: 341-344 [PMID: 18005022]

130 **Wu JJ**, Poon KY. Tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis, psoriatic arthritis, or both. *J Drugs Dermatol* 2014; **13**: 932-934 [PMID: 25116971]

131 **Wu JJ**, Poon KY, Bebchuk JD. Association between the type and length of tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis. *J Drugs Dermatol* 2013; **12**: 899-903 [PMID: 23986163]

**P-Reviewer:** Castillo RL **S-Editor:** Ji FF **L-Editor: E-Editor:**

**Table 1 Role of inflammatory biomarkers in psoriasis, non-alcoholic fatty liver disease and cardiovascular diseases**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Psoriasis** | **CVD** | **NAFLD** |
| **TNF-**alpha | * Keratinocyte proliferation
* Pro-inflammatory cytokines’ production
* Expression of vascular endothelial cell adhesion molecules
* Angiogenesis
 | LDL transcytosis  | IRS-1 phosphorylation Insulin-resistanceHepatic fibrogenesis  |
| **IL-1**  |  Keratinocyte proliferation * Pro-inflammatory cytokines’ production
* Expression of vascular endothelial cell adhesion molecules
 | * Synthesis of IL-6, fibrinogen, RCP
* Expression of adhesion molecules (ICAM, VCAM)
 | * Activation of MAP and ERK pathways
 |
| **IL-6**  | * Pro-inflammatory cytokines (TNF-alpha, IL-1, IL-17)
* Dermal and epidermal cells’ growth and differentiation
* T cell migration into the epidermis
 | * Pro-inflammatory

cytokines’ production | Insulin-resistanceHepatic cytokine signaling-3 |
| **Leptin**  | * Keratinocytes’ proliferation
* Promotes Th1 responses
* Angiogenesis
 | * Vascular smooth muscle cells’ migration and proliferation
* Synthesis of TNF-alpha
 | * Activation of JAK-2/IRS-2/PI3-K/Akt pathways
* Leptin-resistance
* Hepatic fibrogenesis
 |
| **Adiponectin** | * Anti-inflammatory cytokines’ production

 **(Reduced levels in PsO)** | * Endothelial NO production
* Endothelial disfunction

 (**Reduced levels in CVD)** |  * Insulin-sensitivity

 **(Reduced levels in NAFLD)** |
| **Resistin** | * Pro-inflammatory cytokines’ production
 | * Arterial inflammation
* Vascular smooth muscle cell proliferation
* Endothelial dysfunction
 | * Insulin-resistance

 (Controversial data on NAFLD) |
| **Visfatin** |  |  | * Protection toward liver injury (?)

 (not altered in the early stage) |
| **IL-17** | * Pro-inflammatory cytokines’ production
* Expression of vascular endothelial cell adhesion molecules
 | * Atherosclerotic plaque vulnerability
 | Hepatic steatosis * Synthesis of pro-inflammatory cytokines
 |
| **VEGF** | * Keratinocytes’ proliferation
* Angiogenesis
 |  | * Microvascular changes implicated in the hepatic disease (fibrosis to cirrhosis)
 |

CVD: Cardiovascular disease; NAFLD: Non-alcoholic fatty liver disease; LDL: Low density lipoprotein; IRS-1: Insulin receptor substrate 1; MAPK: Mitogen-activated protein; ERK: Extracellular signal-regulated kinase; JAK: Janus kinase-signal transducers; VEGF: Vascular endothelial growth factor; IL: Interleukin; TNF: Tumor necrosis factor.

****

**Figure 1 Psoriasis, non-alcoholic fatty liver disease, cardiovascular diseases and cardiovascular risk factors: A unique inflammatory background.** CVD: Cardiovascular disease; NAFLD: Non-alcoholic fatty liver disease; VEGF: Vascular endothelial growth factor; IL: Interleukin; TNF: Tumor necrosis factor.